Global presence. We have offices located around the globe to support our international customers. Our customers are our inspiration Our desire to innovate is driven by our customers passion in their fields.
Leading the way in molecular testing Our product portfolio supports our customers across the continuum of molecular testing in molecular diagnostics and life sciences. Discover our products. We integrate sustainable practices into every aspect of our business, from reducing our environmental impact and creating healthy, high performance workplaces to being a good corporate citizen.
Sample to Insight We call our strategic framework Sample to Insight. Related content. Find financial reports, quarterly earnings presentations, analyst data and upcoming events. Meet our customers and be fascinated by their science.
Sign up to attend. Syndromic testing Respiratory. COVID and influenza-like illnesses will converge this respiratory season. Visit our resource page to learn how we can support you. Explore resources. These new wet-lab verified LNA-based qPCR genotyping assays rapidly detect the variants of concern, generating results on the same day. Get the assays. Featured Products. View Product. See Product. Discover more. Explore Demo. The company's new business plan helped the company focus not only its research and development resources but its sales and marketing budget as well.
At the same time, the company continued to expand its array of products as it adapted its patented technology to the needs of the various branches of biotechnology research. In , Qiagen launched a new line of so-called BioRobot workstations. The BioRobot was intended to automate a number of the steps in the DNA purification process, freeing up researchers' time.
Although the company's automated equipment remained a sideline to its main consumable products business, Qiagen continued to develop new automated equipment across a wide range of laboratory processes. Qiagen went public in , taking a listing on the NASDAQ stock exchange, an offering that allowed two of the original four partners to cash out.
The public offerings gave Qiagen the financing to begin expanding its operations into new biotechnology areas. One of the company's first moves was to expand its automated process capacity with the acquisition of Rosys AG, based in Switzerland, which the company combined into a new subsidiary, Qiagen Instruments AG.
That subsidiary produced a new successor to the original BioRobot in and continued to develop automated instruments for the biomedical research laboratory. Recognizing the growing maturation of its core plasmid market, Qiagen began making steps to gain expertise in other fast-growing and complementary biotechnology areas. At the end of , the company acquired a new product area when it bought Seattle-based Rapigene, bringing Qiagen that company's Masscode screening technology for single nucleotide polymorphisms SNP.
The addition of Rapigene, which saw its name changed to Qiagen Genomics Inc. Qiagen also was forming a number of strategic partnerships and alliances, joining with such other companies as Evotec, Zeptosens, Affymetrix, and others. In , the company joined with Becton, Dickinson and Company to create the joint venture partnership PreAnalytiX in order to create standardized systems for nucleic acid collecting, stabilizing, and cleansing.
Aiding this growth was a continued series of strategic alliances and new acquisitions. With the biotechnology sector set to revolutionize much of medical care and the pharmaceutical industry in the 21st century, Qiagen was well positioned to maintain its position as a leading player in the biotech boom.
Toggle navigation. User Contributions:. Comment about this article, ask questions, or add new information about this topic: Name:. E-mail: Show my email publicly.
0コメント